PL2273985T3 - Kapsułka do zapobiegania chorobom układu sercowo-naczyniowego - Google Patents

Kapsułka do zapobiegania chorobom układu sercowo-naczyniowego

Info

Publication number
PL2273985T3
PL2273985T3 PL09724677T PL09724677T PL2273985T3 PL 2273985 T3 PL2273985 T3 PL 2273985T3 PL 09724677 T PL09724677 T PL 09724677T PL 09724677 T PL09724677 T PL 09724677T PL 2273985 T3 PL2273985 T3 PL 2273985T3
Authority
PL
Poland
Prior art keywords
capsule
prevention
cardiovascular diseases
cardiovascular
diseases
Prior art date
Application number
PL09724677T
Other languages
English (en)
Inventor
Marta Guerrero
Anna Orriols
Pablo Martín
Manuel Raga
Original Assignee
Ferrer Int
Cnic Fundacion Centro Nac De Investigaciones Cardiovasculares Carlos Iii
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40010466&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2273985(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferrer Int, Cnic Fundacion Centro Nac De Investigaciones Cardiovasculares Carlos Iii filed Critical Ferrer Int
Publication of PL2273985T3 publication Critical patent/PL2273985T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL09724677T 2008-03-28 2009-03-25 Kapsułka do zapobiegania chorobom układu sercowo-naczyniowego PL2273985T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08153615 2008-03-28
PCT/EP2009/053545 WO2009118359A2 (en) 2008-03-28 2009-03-25 Capsule for the prevention of cardiovascular diseases
EP09724677.1A EP2273985B1 (en) 2008-03-28 2009-03-25 Capsule for the prevention of cardiovascular diseases

Publications (1)

Publication Number Publication Date
PL2273985T3 true PL2273985T3 (pl) 2016-08-31

Family

ID=40010466

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09724677T PL2273985T3 (pl) 2008-03-28 2009-03-25 Kapsułka do zapobiegania chorobom układu sercowo-naczyniowego

Country Status (34)

Country Link
US (1) US8753680B2 (pl)
EP (1) EP2273985B1 (pl)
JP (1) JP2011515445A (pl)
KR (1) KR20110007602A (pl)
CN (1) CN101980701A (pl)
AR (1) AR071094A1 (pl)
AU (1) AU2009228832A1 (pl)
BR (1) BRPI0909254A2 (pl)
CA (1) CA2720800C (pl)
CL (1) CL2009000767A1 (pl)
CO (1) CO6311069A2 (pl)
CR (1) CR11736A (pl)
CY (1) CY1117556T1 (pl)
DK (1) DK2273985T3 (pl)
EC (1) ECSP10010562A (pl)
ES (1) ES2569553T3 (pl)
GT (1) GT201000275A (pl)
HN (1) HN2010001979A (pl)
HR (1) HRP20160416T1 (pl)
HU (1) HUE028919T2 (pl)
IL (1) IL208455A0 (pl)
IS (1) IS8932A (pl)
MA (1) MA32347B1 (pl)
MX (1) MX2010010479A (pl)
NI (1) NI201000159A (pl)
NZ (1) NZ588239A (pl)
PL (1) PL2273985T3 (pl)
RU (1) RU2477123C2 (pl)
SI (1) SI2273985T1 (pl)
SV (1) SV2010003684A (pl)
TW (1) TW200944251A (pl)
UA (1) UA99758C2 (pl)
UY (1) UY31741A (pl)
WO (1) WO2009118359A2 (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201005325A2 (tr) * 2010-06-30 2012-01-23 Bi̇lgi̇ç Mahmut Atorvastatin ve aspirin içeren farmasötik formülasyonlar
FR2967577B1 (fr) * 2010-11-18 2013-07-12 Advicenne Pharma Composition pharmaceutique comprenant du sel de bicarbonate, et son utilisation comme medicament
KR101298788B1 (ko) * 2011-03-15 2013-08-22 보령제약 주식회사 안정성이 개선된 복합제제
KR101378973B1 (ko) * 2012-04-13 2014-03-28 한미약품 주식회사 구형에 가까운 형태의 다중 투여 단위 정제를 포함하는 경질 캡슐 복합 제형 및 이의 제조방법
KR20140030505A (ko) * 2012-08-31 2014-03-12 한미약품 주식회사 이베살탄 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 약제학적 캡슐 복합제제
CN103006612B (zh) * 2012-12-28 2014-07-02 石雷 一种赖诺普利迟释缓释片剂及其制备方法
EP2810644A1 (en) * 2013-06-06 2014-12-10 Ferrer Internacional, S.A. Oral formulation for the treatment of cardiovascular diseases
JP6465201B2 (ja) * 2015-03-05 2019-02-06 日本電気株式会社 無線設備の故障判定方法及び移動体無線システム
BE1023011B1 (nl) * 2015-08-05 2016-11-04 Nordic Specialty Pharma Bvba Acetylsalicylzuur tablet met onmiddellijke afgifte
ES2695503B2 (es) 2017-06-30 2020-05-08 Pharmalink S L Formulaciones encapsuladas
KR102042626B1 (ko) 2019-06-26 2019-11-11 한미약품 주식회사 이베살탄 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 약제학적 캡슐 복합제제
JP2023553274A (ja) * 2020-11-18 2023-12-21 エフビー－エイチアールエス リミテッド ライアビリティ カンパニー ドフェチリド及びメキシレチンを含有する組成物並びにその使用
HRP20240628T1 (hr) 2022-06-30 2024-09-27 Ferrer Internacional, S.A. Oralne kapsule koje sadrže tablete atorvastatina koje pokazuju odgovarajući profil otapanja i bioraspoloživost
CN115671077B (zh) * 2022-11-18 2024-09-17 乐普药业股份有限公司 一种预防心脑血管疾病的复方微丸胶囊及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3739690A1 (de) 1987-11-24 1989-06-08 Hoechst Ag Stabilisierte arzneistoffe, verfahren zu ihrer herstellung sowie stabile arzneizubereitungen
JP2544052B2 (ja) * 1991-12-18 1996-10-16 日本エランコ株式会社 硬質ゼラチンカプセルへの錠剤充填装置
SE9702000D0 (sv) * 1997-05-28 1997-05-28 Astra Ab New pharmaceutical formulation
US6235311B1 (en) * 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
PL202884B1 (pl) * 2000-02-10 2009-07-31 Bpsi Holdings Nietoksyczna, jadalna, powłokotwórcza kompozycja proszkowa zabezpieczająca przed działaniem soku żołądkowego, sposób sporządzania wodnego układu dyspersyjnego oraz sposób powlekania substratów
US6669955B2 (en) * 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US6576256B2 (en) * 2001-08-28 2003-06-10 The Brigham And Women's Hospital, Inc. Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
WO2004080488A2 (de) 2003-03-10 2004-09-23 Bayer Healthcare Ag Kombinationspräparate von acetylsalicylsäure mit einem hmg-coa-reduktase
EP1648422A4 (en) * 2003-07-28 2007-09-19 Reddys Lab Inc Dr TREATMENT AND PREVENTION OF CARDIOVASCULAR ACCIDENTS
WO2005019286A1 (ja) * 2003-08-20 2005-03-03 Shionogi & Co., Ltd. 新規コーティング組成物
US20070009591A1 (en) * 2005-07-07 2007-01-11 Trivedi Jay S ACE inhibitor formulation
US20070116756A1 (en) * 2005-11-23 2007-05-24 Dr. Reddy's Laboratories Limited Stable pharmaceutical compositions
US7427414B2 (en) * 2006-01-18 2008-09-23 Astron Research Limited Modified release oral dosage form using co-polymer of polyvinyl acetate
US20080014264A1 (en) * 2006-07-13 2008-01-17 Ucb, S.A. Novel pharmaceutical compositions comprising levetiracetam
WO2009022821A2 (en) * 2007-08-13 2009-02-19 Hanall Pharmaceutical Company. Ltd Combination preparation comprising inhibitor of hmg-coa reductase and aspirin and method for manufacturing the same

Also Published As

Publication number Publication date
HUE028919T2 (en) 2017-01-30
HRP20160416T1 (hr) 2016-06-17
RU2010144131A (ru) 2012-05-10
HN2010001979A (es) 2013-07-01
WO2009118359A2 (en) 2009-10-01
WO2009118359A3 (en) 2010-05-06
ES2569553T3 (es) 2016-05-11
AU2009228832A1 (en) 2009-10-01
CA2720800C (en) 2013-07-30
UA99758C2 (ru) 2012-09-25
EP2273985B1 (en) 2016-02-17
CO6311069A2 (es) 2011-08-22
MX2010010479A (es) 2011-02-22
IS8932A (is) 2010-10-05
ECSP10010562A (es) 2011-04-29
AR071094A1 (es) 2010-05-26
CA2720800A1 (en) 2009-10-01
JP2011515445A (ja) 2011-05-19
EP2273985A2 (en) 2011-01-19
IL208455A0 (en) 2010-12-30
UY31741A (es) 2009-12-14
CN101980701A (zh) 2011-02-23
BRPI0909254A2 (pt) 2017-01-10
US8753680B2 (en) 2014-06-17
SI2273985T1 (sl) 2016-06-30
SV2010003684A (es) 2011-03-31
KR20110007602A (ko) 2011-01-24
NI201000159A (es) 2011-08-02
DK2273985T3 (en) 2016-04-25
MA32347B1 (fr) 2011-06-01
US20110086094A1 (en) 2011-04-14
CY1117556T1 (el) 2017-04-26
CL2009000767A1 (es) 2009-08-14
GT201000275A (es) 2015-09-30
TW200944251A (en) 2009-11-01
RU2477123C2 (ru) 2013-03-10
CR11736A (es) 2011-05-11
NZ588239A (en) 2011-09-30

Similar Documents

Publication Publication Date Title
IL208455A0 (en) Capsule for the prevention of cardiovascular diseases
PL2118074T3 (pl) Związki chemiczne do celów profilaktyki i leczenia chorób układu sercowo-naczyniowego
AP2860A (en) Carbazole compounds and therapeutic uses of the compounds
ZA201004793B (en) Capsule formulation
ZA201008536B (en) Suppression of neuroendocrine diseases
GB0921075D0 (en) Novel combination of the therapeutic agents
SI2151428T1 (sl) Postopek za pripravo agomelatina
PT1992575E (pt) Cápsula para produtos de infusão
EG26332A (en) Process for the preparation of benzonoprons
ZA201007362B (en) Conjugates for the treatment of mesothelioma
IL207247A0 (en) Use of ranolazine for the treatment of cardiovascular disease
PT2151429E (pt) Novo processo de síntese da agomelatina
GB2471453B (en) Fragrance capsule
PL2307380T3 (pl) Pochodne N’-nitroksyalkilonikotynamidu do leczenia chorób układu sercowo-naczyniowego
PL2896614T3 (pl) Sposoby i związki do wytwarzania normorfinanów
IL211382A0 (en) Process for the preparation of ethanedinitrile
GB0716840D0 (en) Treatment of cardiovascular disease
PL384700A1 (pl) Sposób syntezy 1-propenyloksyalkoholu
PL384973A1 (pl) Sposób otrzymywania erytrytolu
GB0911657D0 (en) Novel compounds and improved treatmemts for cardiac and cardiovascular disease
PH32007000328S1 (en) Capsule chamber
GB0809319D0 (en) The treatment of puritus
PL384594A1 (pl) Sposób otrzymywania polisacharydu nieskrobiowego ze zbóż
PL387383A1 (pl) Sposób otrzymywania fosfolipidów
GB0812613D0 (en) Process for the preparation of 1-deoxyidonojirimycin